ASEAN Member States Virtually Assemble in the recent Drug Price Transparency Workshop

The Association of Southeast Asian Nations (ASEAN) Member States, comprising Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam, convened in a two-day online workshop to ensure fair prices and effective financing of medicines and health technologies with the aim to fortify health systems and to achieve wider Universal Health Coverage on April 6-7, 2022.

DOH Announces Full Implementation of Drug Price Caps with Executive Order No. 155

The Department of Health (DOH) announces the full implementation of drug price caps starting March 23, 2022 through Executive Order (EO) No. 155 signed by President Rodrigo Duterte. This brings the total number of drugs with maximum drug retail price to 121 molecules or 204 drug formulas, following the first round of price regulation implemented in June 2020 with the signing of EO No. 104 which covered 87 molecules.

Advisory on the Draft Administrative Order Entitled “Guidelines in the Implementation of the Guidelines in the Implementation of the RA 7581 or the Price Act Provisions for Medicines and Medical Devices”

ADVISORY August 11, 2021    DRAFT ADMINISTRATIVE ORDER ENTITLED “GUIDELINES IN THEIMPLEMENTATION OF THE GUIDELINES IN THE IMPLEMENTATION OF THERA 7581 OR THE PRICE ACT PROVISIONS FOR MEDICINES AND MEDICALDEVICES continue reading : Advisory on the Draft Administrative Order Entitled “Guidelines in the Implementation of the Guidelines in the Implementation of the RA 7581 or the Price Act Provisions for Medicines and Medical Devices”

Advisory on the Draft Administrative Order Entitled “Mandatory Provision of Fairly Priced Generics in Support of the Universal Health Care”

ADVISORY December 11, 2020    DRAFT ADMINISTRATIVE ORDER ENTITLED “MANDATORY PROVISION OF FAIRLY PRICED GENERICS IN SUPPORT OF THE UNIVERSAL HEALTH CARE” To achieve the goals of the Universal Health continue reading : Advisory on the Draft Administrative Order Entitled “Mandatory Provision of Fairly Priced Generics in Support of the Universal Health Care”